Base de dados : MEDLINE
Pesquisa : D02.455.526.728.650 [Categoria DeCS]
Referências encontradas : 2859 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 286 ir para página                         

  1 / 2859 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28220519
[Au] Autor:Cancelas JA; Gottschall JL; Rugg N; Graminske S; Schott MA; North A; Huang N; Mufti N; Erickson A; Rico S; Corash L
[Ad] Endereço:Hoxworth Blood Center, Cincinnati, OH, USA.
[Ti] Título:Red blood cell concentrates treated with the amustaline (S-303) pathogen reduction system and stored for 35 days retain post-transfusion viability: results of a two-centre study.
[So] Source:Vox Sang;112(3):210-218, 2017 Apr.
[Is] ISSN:1423-0410
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND OBJECTIVES: Pathogen reduction technology using amustaline (S-303) was developed to reduce the risk of transfusion-transmitted infection and adverse effects of residual leucocytes. In this study, the viability of red blood cells (RBCs) prepared with a second-generation process and stored for 35 days was evaluated in two different blood centres. MATERIALS AND METHODS: In a single-blind, randomized, controlled, two-period crossover study (n = 42 healthy subjects), amustaline-treated (Test) or Control RBCs were prepared in random sequence and stored for 35 days. On day 35, an aliquot of Cr/ Tc radiolabeled RBCs was transfused. In a subgroup of 26 evaluable subjects, 24-h RBC post-transfusion recovery, mean life span, median life span (T ) and life span area under the curve (AUC) were analysed. RESULTS: The mean 24-h post-transfusion recovery of Test and Control RBCs was comparable (83·2 ± 5·2 and 84·9 ± 5·9%, respectively; P = 0·06) and consistent with the US Food and Drug Administration (FDA) criteria for acceptable RBC viability. There were differences in the T between Test and Control RBCs (33·5 and 39·7 days, respectively; P < 0·001), however, these were within published reference ranges of 28-35 days. The AUC (per cent surviving × days) for Test and Control RBCs was similar (22·6 and 23·1 per cent surviving cells × days, respectively; P > 0·05). Following infusion of Test RBCs, there were no clinically relevant abnormal laboratory values or adverse events. CONCLUSION: RBCs prepared using amustaline pathogen reduction meet the FDA criteria for post-transfusion recovery and are metabolically and physiologically appropriate for transfusion following 35 days of storage.
[Mh] Termos MeSH primário: Acridinas/farmacologia
Preservação de Sangue
Eritrócitos/efeitos dos fármacos
Compostos de Mostarda Nitrogenada/farmacologia
[Mh] Termos MeSH secundário: Acridinas/química
Adulto
Idoso
Área Sob a Curva
Sobrevivência Celular/efeitos dos fármacos
Isótopos do Cromo/química
Estudos Cross-Over
Contagem de Eritrócitos
Transfusão de Eritrócitos/efeitos adversos
Eritrócitos/química
Eritrócitos/citologia
Eritrócitos/metabolismo
Feminino
Meia-Vida
Hematoma/etiologia
Seres Humanos
Marcação por Isótopo
Masculino
Viabilidade Microbiana/efeitos dos fármacos
Meia-Idade
Compostos de Mostarda Nitrogenada/química
Curva ROC
Método Simples-Cego
Tecnécio/química
Fatores de Tempo
Inativação de Vírus/efeitos dos fármacos
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 ((N,N-bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionate); 0 (Acridines); 0 (Chromium Isotopes); 0 (Nitrogen Mustard Compounds); 7440-26-8 (Technetium)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171114
[Lr] Data última revisão:
171114
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170222
[St] Status:MEDLINE
[do] DOI:10.1111/vox.12500


  2 / 2859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28164306
[Au] Autor:Laughhunn A; Santa Maria F; Broult J; Lanteri MC; Stassinopoulos A; Musso D; Aubry M
[Ad] Endereço:Cerus Corporation, Concord, California.
[Ti] Título:Amustaline (S-303) treatment inactivates high levels of Zika virus in red blood cell components.
[So] Source:Transfusion;57(3pt2):779-789, 2017 Mar.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The potential for Zika virus (ZIKV) transfusion-transmission (TT) has been demonstrated in French Polynesia and Brazil. Pathogen inactivation (PI) of blood products is a proactive strategy to inactivate TT pathogens including arboviruses. Inactivation of West Nile, dengue, Zika, and chikungunya viruses was previously demonstrated by photochemical treatment with amotosalen and ultraviolet A (UVA) illumination. In this study, we evaluated ZIKV inactivation in red blood cell (RBC) components by a chemical approach that uses amustaline (S-303) and glutathione (GSH). STUDY DESIGN AND METHODS: RBC components were spiked with a high titer of ZIKV. Viral titers (infectivity) and ZIKV RNA loads (reverse transcription-polymerase chain reaction) were measured in spiked RBCs before and after S-303 and GSH treatment and confirmed using repetitive passages in cell culture. A mock-treated arm validated the approach by demonstrating stability of the virus (infectivity and RNA load) during the process. RESULTS: The mean ZIKV infectivity titer and RNA load in RBCs were 5.99 ± 0.2 log 50% tissue culture infectious dose (TCID )/mL and 7.75 ± 0.16 log genomic equivalents/mL before inactivation. No infectivity was detected immediately after S-303 and GSH treatment and after five serial passages in cell culture. CONCLUSION: Complete ZIKV inactivation of more than 5.99 log TCID /mL in RBCs was achieved using S-303 and GSH at levels higher than those found in asymptomatic ZIKV-infected blood donors. Therefore, the S-303 and GSH PI system is promising for mitigating the risk of ZIKV TT.
[Mh] Termos MeSH primário: Acridinas/farmacologia
Desinfecção/métodos
Eritrócitos/virologia
Compostos de Mostarda Nitrogenada/farmacologia
RNA Viral/sangue
Inativação de Vírus
Zika virus
[Mh] Termos MeSH secundário: Acridinas/química
Feminino
Seres Humanos
Masculino
Compostos de Mostarda Nitrogenada/química
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 ((N,N-bis(2-chloroethyl))-2-aminoethyl-3-((acridin-9-yl)amino)propionate); 0 (Acridines); 0 (Nitrogen Mustard Compounds); 0 (RNA, Viral)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170621
[Lr] Data última revisão:
170621
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170207
[St] Status:MEDLINE
[do] DOI:10.1111/trf.13993


  3 / 2859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28140568
[Au] Autor:Stornetta A; Villalta PW; Gossner F; Wilson WR; Balbo S; Sturla SJ
[Ad] Endereço:Department of Health Sciences and Technology, ETH Zurich , Schmelzbergstrasse 9, 8092 Zurich, Switzerland.
[Ti] Título:DNA Adduct Profiles Predict in Vitro Cell Viability after Treatment with the Experimental Anticancer Prodrug PR104A.
[So] Source:Chem Res Toxicol;30(3):830-839, 2017 Mar 20.
[Is] ISSN:1520-5010
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:PR104A is an experimental DNA-alkylating hypoxia-activated prodrug that can also be activated in an oxygen-independent manner by the two-electron aldo-keto reductase 1C3. Nitroreduction leads to the formation of cytotoxic hydroxylamine (PR104H) and amine (PR104M) metabolites, which induce DNA mono and cross-linked adducts in cells. PR104A-derived DNA adducts can be utilized as drug-specific biomarkers of efficacy and as a mechanistic tool to elucidate the cellular and molecular effects of PR104A. Toward this goal, a mass spectrometric bioanalysis approach based on a stable isotope-labeled adduct mixture (SILAM) and selected reaction monitoring (SRM) data acquisition for relative quantitation of PR104A-derived DNA adducts in cells was developed. Use of this SILAM-based approach supported simultaneous relative quantitation of 33 PR104A-derived DNA adducts in the same sample, which allowed testing of the hypothesis that the enhanced cytotoxicity, observed by preconditioning cells with the transcription-activating isothiocyanate sulforaphane, is induced by an increased level of DNA adducts induced by PR104H and PR104M, but not PR104A. By applying the new SILAM-SRM approach, we found a 2.4-fold increase in the level of DNA adducts induced by PR104H and PR104M in HT-29 cells preconditioned with sulforaphane and a corresponding 2.6-fold increase in cytotoxicity. These results suggest that DNA adduct levels correlate with drug potency and underly the possibility of monitoring PR104A-derived DNA adducts as biomarkers of efficacy.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Adutos de DNA
Compostos de Mostarda Nitrogenada/farmacologia
Pró-Fármacos/farmacologia
[Mh] Termos MeSH secundário: Células HT29
Seres Humanos
Técnicas In Vitro
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (DNA Adducts); 0 (Nitrogen Mustard Compounds); 0 (PR-104A); 0 (Prodrugs)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170714
[Lr] Data última revisão:
170714
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170201
[St] Status:MEDLINE
[do] DOI:10.1021/acs.chemrestox.6b00412


  4 / 2859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27936622
[Au] Autor:Stornetta A; Zimmermann M; Cimino GD; Henderson PT; Sturla SJ
[Ad] Endereço:Department of Health Sciences and Technology, ETH Zurich , Schmelzbergstrasse 9, 8092 Zurich, Switzerland.
[Ti] Título:DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.
[So] Source:Chem Res Toxicol;30(1):388-409, 2017 01 17.
[Is] ISSN:1520-5010
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Biomarker-driven drug selection plays a central role in cancer drug discovery and development, and in diagnostic strategies to improve the use of traditional chemotherapeutic drugs. DNA-modifying anticancer drugs are still used as first line medication, but drawbacks such as resistance and side effects remain an issue. Monitoring the formation and level of DNA modifications induced by anticancer drugs is a potential strategy for stratifying patients and predicting drug efficacy. In this perspective, preclinical and clinical data concerning the relationship between drug-induced DNA adducts and biological response for platinum drugs and combination therapies, nitrogen mustards and half-mustards, hypoxia-activated drugs, reductase-activated drugs, and minor groove binding agents are presented and discussed. Aspects including measurement strategies, identification of adducts, and biological factors that influence the predictive relationship between DNA modification and biological response are addressed. A positive correlation between DNA adduct levels and response was observed for the majority of the studies, demonstrating the high potential of using DNA adducts from anticancer drugs as mechanism-based biomarkers of susceptibility, especially as bioanalysis approaches with higher sensitivity and throughput emerge.
[Mh] Termos MeSH primário: Antineoplásicos/uso terapêutico
Adutos de DNA/metabolismo
[Mh] Termos MeSH secundário: Animais
Biomarcadores/metabolismo
Seres Humanos
Hipóxia/metabolismo
Compostos de Mostarda Nitrogenada/uso terapêutico
Oxirredutases/metabolismo
Compostos de Platina/uso terapêutico
Medicina de Precisão
Pró-Fármacos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Biomarkers); 0 (DNA Adducts); 0 (Nitrogen Mustard Compounds); 0 (Platinum Compounds); 0 (Prodrugs); EC 1.- (Oxidoreductases)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170426
[Lr] Data última revisão:
170426
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161213
[St] Status:MEDLINE
[do] DOI:10.1021/acs.chemrestox.6b00380


  5 / 2859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27871834
[Au] Autor:Yang MM; Wilson WR; Wu Z
[Ad] Endereço:School of Pharmacy, The University of Auckland, Auckland 1142, New Zealand.
[Ti] Título:pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells.
[So] Source:Int J Pharm;516(1-2):323-333, 2017 Jan 10.
[Is] ISSN:1873-3476
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:This paper aims to develop and evaluate a pH-sensitive PEGylated liposomal (pPSL) system for tumor-targeted intracellular delivery of SN25860, a weakly acidic, poorly water-soluble dinitrobenzamide mustard prodrug which is activated by the E. coli nitroreductase nfB. pPSL and non pH-sensitive liposomes (nPSL), as reference, were formulated by thin-film hydration; an active drug loading method was developed with the aid of solubilizers. Cytotoxicity was evaluated in an nfsB-transfected EMT6 mouse mammary carcinoma cell line. Cellular uptake of liposomes was evaluated by both high performance liquid chromatography and flow cytometry. Intracellular trafficking was visualised by confocal microscopy. High drug loading (7.0±0.2% w/w) was achieved after systematic optimization of drug loading conditions. pPSL-SN25860 demonstrated a 21 and 24- fold increase in antiproliferative potency compared to nPSL-SN25860 and free drug, respectively. Cells treated with pPSL had a 1.6-2.5- fold increase in intracellular drug concentration compared to nPSL. This trend was consistent with flow cytometry results. Cells treated with chlorpromazine demonstrated reduced uptake of both nPSL (40%) and pPSL (46%), indicating clathrin-mediated endocytosis was the major pathway. Confocal microscopy showed that pPSL had not only undergone faster and greater endocytosis than nPSL but was also homogeneously distributed in the cytosol and nuclei suggesting endosome escape, in contrast to nPSL.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Benzamidas/administração & dosagem
Sistemas de Liberação de Medicamentos
Neoplasias Mamárias Animais/tratamento farmacológico
Compostos de Mostarda Nitrogenada/administração & dosagem
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacocinética
Antineoplásicos/farmacologia
Benzamidas/farmacocinética
Benzamidas/farmacologia
Linhagem Celular Tumoral
Proliferação Celular/efeitos dos fármacos
Cromatografia Líquida de Alta Pressão/métodos
Endossomos/metabolismo
Feminino
Citometria de Fluxo
Concentração de Íons de Hidrogênio
Lipossomos
Neoplasias Mamárias Animais/patologia
Camundongos
Microscopia Confocal
Compostos de Mostarda Nitrogenada/farmacocinética
Compostos de Mostarda Nitrogenada/farmacologia
Polietilenoglicóis/química
Pró-Fármacos
Solubilidade
Transfecção
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Benzamides); 0 (Liposomes); 0 (Nitrogen Mustard Compounds); 0 (Prodrugs); 30IQX730WE (Polyethylene Glycols)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:170509
[Lr] Data última revisão:
170509
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161123
[St] Status:MEDLINE


  6 / 2859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27783294
[Au] Autor:Popova NA; Kaledin VI; Nikolin VP; Bogdanova LA; Morozkova TS; Tornuev YV
[Ad] Endereço:Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia. pathol@inbox.ru.
[Ti] Título:Different Efficiency of Liposomal Forms with Hydrophilic and Hydrophobic Antitumor Agents in Relation to Solid Transplants of Mouse Tumor and Its Metastases in the Liver.
[So] Source:Bull Exp Biol Med;161(6):811-815, 2016 Oct.
[Is] ISSN:1573-8221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Experiments were performed on the model of transplanted mouse tumor with high incidence of liver metastases. Hydrophilic drug cycloplatam (injected intravenously in liposomes) was more potent than "free cycloplatam" (injected intravenously or intraperitoneally in physiological saline) in inhibiting the growth of natural and experimental metastases in the liver. By contrast, liposomal cycloplatam had lower efficiency than free cycloplatam in suppressing the growth of solid tumor. Liposomal and free cortifen (hydrophobic hormonal cytostatic) produced nearly the same effects on solid tumor growth. Our results suggest that liposomal forms of hydrophobic compounds producing nonselective effect on tumor cells (e.g., actinomycin D or Cosmegen), should not have advantages over free forms.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Corticosterona/análogos & derivados
Neoplasias Hepáticas/tratamento farmacológico
Neoplasias Musculares/tratamento farmacológico
Compostos de Mostarda Nitrogenada/farmacologia
Compostos Organoplatínicos/farmacologia
[Mh] Termos MeSH secundário: Animais
Antineoplásicos/farmacocinética
Linhagem Celular Tumoral
Corticosterona/farmacocinética
Corticosterona/farmacologia
Sistemas de Liberação de Medicamentos
Injeções Intraperitoneais
Injeções Intravenosas
Lipossomos/química
Lipossomos/farmacocinética
Neoplasias Hepáticas/mortalidade
Neoplasias Hepáticas/secundário
Camundongos
Neoplasias Musculares/mortalidade
Neoplasias Musculares/patologia
Transplante de Neoplasias
Compostos de Mostarda Nitrogenada/farmacocinética
Compostos Organoplatínicos/farmacocinética
Análise de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Liposomes); 0 (Nitrogen Mustard Compounds); 0 (Organoplatinum Compounds); 0 (cortifen); 109837-67-4 (cycloplatam); W980KJ009P (Corticosterone)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170209
[Lr] Data última revisão:
170209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161027
[St] Status:MEDLINE


  7 / 2859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
PubMed Central Texto completo
Texto completo
[PMID]:26950072
[Au] Autor:Erzinger MM; Bovet C; Hecht KM; Senger S; Winiker P; Sobotzki N; Cristea S; Beerenwinkel N; Shay JW; Marra G; Wollscheid B; Sturla SJ
[Ad] Endereço:Department of Health Sciences and Technology, ETH Zurich, Zurich, Switzerland.
[Ti] Título:Sulforaphane Preconditioning Sensitizes Human Colon Cancer Cells towards the Bioreductive Anticancer Prodrug PR-104A.
[So] Source:PLoS One;11(3):e0150219, 2016.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The chemoprotective properties of sulforaphane (SF), derived from cruciferous vegetables, are widely acknowledged to arise from its potent induction of xenobiotic-metabolizing and antioxidant enzymes. However, much less is known about the impact of SF on the efficacy of cancer therapy through the modulation of drug-metabolizing enzymes. To identify proteins modulated by a low concentration of SF, we treated HT29 colon cancer cells with 2.5 µM SF. Protein abundance changes were detected by stable isotope labeling of amino acids in cell culture. Among 18 proteins found to be significantly up-regulated, aldo-keto reductase 1C3 (AKR1C3), bioactivating the DNA cross-linking prodrug PR-104A, was further characterized. Preconditioning HT29 cells with SF reduced the EC50 of PR-104A 3.6-fold. The increase in PR-104A cytotoxicity was linked to AKR1C3 abundance and activity, both induced by SF in a dose-dependent manner. This effect was reproducible in a second colon cancer cell line, SW620, but not in other colon cancer cell lines where AKR1C3 abundance and activity were absent or barely detectable and could not be induced by SF. Interestingly, SF had no significant influence on PR-104A cytotoxicity in non-cancerous, immortalized human colonic epithelial cell lines expressing either low or high levels of AKR1C3. In conclusion, the enhanced response of PR-104A after preconditioning with SF was apparent only in cancer cells provided that AKR1C3 is expressed, while its expression in non-cancerous cells did not elicit such a response. Therefore, a subset of cancers may be susceptible to combined food-derived component and prodrug treatments with no harm to normal tissues.
[Mh] Termos MeSH primário: Antineoplásicos/farmacologia
Neoplasias do Colo/patologia
Isotiocianatos/farmacologia
Compostos de Mostarda Nitrogenada/farmacologia
[Mh] Termos MeSH secundário: 3-Hidroxiesteroide Desidrogenases/metabolismo
Membro C3 da Família 1 de alfa-Ceto Redutase
Antineoplásicos/efeitos adversos
Transporte Biológico
Linhagem Celular Tumoral
Diploide
Sinergismo Farmacológico
Regulação Neoplásica da Expressão Gênica/efeitos dos fármacos
Seres Humanos
Hidroxiprostaglandina Desidrogenases/metabolismo
Mucosa Intestinal/citologia
Mucosa Intestinal/efeitos dos fármacos
Isotiocianatos/metabolismo
Compostos de Mostarda Nitrogenada/efeitos adversos
Pró-Fármacos/efeitos adversos
Pró-Fármacos/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Isothiocyanates); 0 (Nitrogen Mustard Compounds); 0 (PR-104A); 0 (Prodrugs); EC 1.1.- (3-Hydroxysteroid Dehydrogenases); EC 1.1.1.- (Hydroxyprostaglandin Dehydrogenases); EC 1.1.1.357 (AKR1C3 protein, human); EC 1.1.1.357 (Aldo-Keto Reductase Family 1 Member C3); GA49J4310U (sulforafan)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160308
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0150219


  8 / 2859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26936530
[Au] Autor:Lopez JP; Shore TB
[Ad] Endereço:a Division of Hematology and Oncology , NewYork-Presbyterian/Weill Cornell Medical College , NY , USA.
[Ti] Título:Bendamustine and stem-cell mobilization: not so bad!
[So] Source:Leuk Lymphoma;57(5):993-4, 2016 May.
[Is] ISSN:1029-2403
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Cloridrato de Bendamustina
Mobilização de Células-Tronco Hematopoéticas
[Mh] Termos MeSH secundário: Antineoplásicos Alquilantes/uso terapêutico
Seres Humanos
Compostos de Mostarda Nitrogenada/uso terapêutico
[Pt] Tipo de publicação:COMMENT; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Alkylating); 0 (Nitrogen Mustard Compounds); 981Y8SX18M (Bendamustine Hydrochloride)
[Em] Mês de entrada:1608
[Cu] Atualização por classe:160421
[Lr] Data última revisão:
160421
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160304
[St] Status:MEDLINE
[do] DOI:10.3109/10428194.2016.1153091


  9 / 2859 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26718494
[Au] Autor:Yang Y; Li C; Fu Y; Liu Y; Zhang Y; Zhang Y; Zhou P; Yuan Y; Zhou S; Li S; Li C
[Ad] Endereço:Department of Molecular Biology and Biochemistry, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China.
[Ti] Título:Redox cycling of a copper complex with benzaldehyde nitrogen mustard-2-pyridine carboxylic acid hydrazone contributes to its enhanced antitumor activity, but no change in the mechanism of action occurs after chelation.
[So] Source:Oncol Rep;35(3):1636-44, 2016 Mar.
[Is] ISSN:1791-2431
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Many anticancer drugs used in the clinical have potent metal chelating ability. The formed metal complex(es) may exhibit improved (or antagonistic) antitumor activity. However, the underlying mechanism has received limited attention. Therefore, investigation of the mechanism involved in the change upon chelation is required to extend our understanding of the effects of various drugs. In the present study, the proliferation inhibition effect of benzaldehyde nitrogen mustard-2-pyridine carboxylic acid hydrazone (BNMPH) and its copper complex on tumor cell lines was investigated. The copper chelate exhibited almost a 10-fold increase in antitumor activity (with IC50 <5 µM). The results showed that both BNMPH and its copper complex induced reactive oxygen species (ROS) generation, and caused upregulation of caspase 8 and Bax as well as the downregulation of Bcl-2, indicating that apoptosis was involved in the cytotoxic effects. DNA fragmentation noted in the comet assay further supported ROS involvement. The present study indicated that BNMPH and its copper complex effectively induced S phase arrest and the cell cycle arrest was associated with the downregulation of cyclin D1. The formation of acidic vesicular organelles (AVOs) and an increase in cleaved LC3-II demonstrated that autophagy occurred in the HepG2 cells treated with the agents. Taken together, BNMPH and its copper complex exhibited proliferation inhibition via apoptosis, cell cycle arrest and autophagy, which was dependent on ROS. The enhanced antitumor activity of the copper complex was due to its redox-cycling ability, but the mechanism was not altered compared to BNMPH. Our findings may significantly contribute to the understanding of the anti-proliferative effect of BNMPH and its copper complex.
[Mh] Termos MeSH primário: Antineoplásicos/administração & dosagem
Autofagia/efeitos dos fármacos
Hidrazonas/administração & dosagem
Neoplasias Hepáticas/tratamento farmacológico
Compostos de Mostarda Nitrogenada/administração & dosagem
[Mh] Termos MeSH secundário: Caspase 8/biossíntese
Pontos de Checagem do Ciclo Celular/efeitos dos fármacos
Complexos de Coordenação/administração & dosagem
Cobre/administração & dosagem
Fragmentação do DNA/efeitos dos fármacos
Regulação Neoplásica da Expressão Gênica
Células Hep G2
Seres Humanos
Neoplasias Hepáticas/genética
Neoplasias Hepáticas/patologia
Espécies Reativas de Oxigênio/metabolismo
Proteína X Associada a bcl-2/biossíntese
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Antineoplastic Agents); 0 (Coordination Complexes); 0 (Hydrazones); 0 (Nitrogen Mustard Compounds); 0 (Reactive Oxygen Species); 0 (bcl-2-Associated X Protein); 0 (benzaldehyde nitrogen mustard-2-pyridine carboxyl acid hydrazone); 789U1901C5 (Copper); EC 3.4.22.- (CASP8 protein, human); EC 3.4.22.- (Caspase 8)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:161230
[Lr] Data última revisão:
161230
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160101
[St] Status:MEDLINE
[do] DOI:10.3892/or.2015.4530


  10 / 2859 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:26692166
[Au] Autor:Groehler A; Villalta PW; Campbell C; Tretyakova N
[Ad] Endereço:Department of Medicinal Chemistry, ‡Department of Pharmacology, and §Masonic Cancer Center, University of Minnesota , Minneapolis, Minnesota 55455, United States.
[Ti] Título:Covalent DNA-Protein Cross-Linking by Phosphoramide Mustard and Nornitrogen Mustard in Human Cells.
[So] Source:Chem Res Toxicol;29(2):190-202, 2016 Feb 15.
[Is] ISSN:1520-5010
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:N,N-Bis-(2-chloroethyl)-phosphorodiamidic acid (phosphoramide mustard, PM) and N,N-bis-(2-chloroethyl)-amine (nornitrogen mustard, NOR) are the two biologically active metabolites of cyclophosphamide, a DNA alkylating drug commonly used to treat lymphomas, breast cancer, certain brain cancers, and autoimmune diseases. PM and NOR are reactive bis-electrophiles capable of cross-linking cellular biomolecules to form covalent DNA-DNA and DNA-protein cross-links (DPCs). In the present work, a mass spectrometry-based proteomics approach was employed to characterize PM- and NOR-mediated DNA-protein cross-linking in human cells. Following treatment of human fibrosarcoma cells (HT1080) with cytotoxic concentrations of PM, over 130 proteins were found to be covalently trapped to DNA, including those involved in transcriptional regulation, RNA splicing/processing, chromatin organization, and protein transport. HPLC-ESI(+)-MS/MS analysis of proteolytic digests of DPC-containing DNA from NOR-treated cells revealed a concentration-dependent formation of N-[2-[cysteinyl]ethyl]-N-[2-(guan-7-yl)ethyl]amine (Cys-NOR-N7G) conjugates, confirming that it cross-links cysteine thiols of proteins to the N7 position of guanines in DNA. Cys-NOR-N7G adduct numbers were higher in NER-deficient xeroderma pigmentosum cells (XPA) as compared with repair proficient cells. Furthermore, both XPA and FANCD2 deficient cells were sensitized to PM treatment as compared to that of wild type cells, suggesting that Fanconi anemia and nucleotide excision repair pathways are involved in the removal of cyclophosphamide-induced DNA damage.
[Mh] Termos MeSH primário: Alquilantes/química
DNA/química
Compostos de Mostarda Nitrogenada/química
Mostardas de Fosforamida/química
Proteínas/química
[Mh] Termos MeSH secundário: Linhagem Celular Tumoral
Cromatografia Líquida de Alta Pressão
DNA/metabolismo
Adutos de DNA/análise
Seres Humanos
Peptídeos/análise
Proteínas/metabolismo
Proteômica
Espectrometria de Massas por Ionização por Electrospray
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (Alkylating Agents); 0 (DNA Adducts); 0 (Nitrogen Mustard Compounds); 0 (Peptides); 0 (Phosphoramide Mustards); 0 (Proteins); 10159-53-2 (phosphoramide mustard); 9007-49-2 (DNA); IHV3I38UXH (nornitrogen mustard)
[Em] Mês de entrada:1610
[Cu] Atualização por classe:170220
[Lr] Data última revisão:
170220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:151223
[St] Status:MEDLINE
[do] DOI:10.1021/acs.chemrestox.5b00430



página 1 de 286 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde